Monday, June 18

7:30 p.m.-9:00 p.m. Keynote Presentations and Discussion:
Pancreatic Cancer 2012 – Do We Have the Tools and Knowledge to Defeat It?

Welcome

7:30 p.m. Fatal attraction: A new story featuring the immune system and pancreatic cancer
Elizabeth M. Jaffee, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD

8:00 p.m. The relentless pursuit approach
Daniel D. Von Hoff, Translational Genomics Research Institute, Phoenix, AZ

8:30 p.m. Discussion

9:00 p.m.-10:30 p.m. Dessert Reception

Tuesday, June 19

7:00 a.m.-8:00 a.m. Continental Breakfast and Meet-the-Expert Roundtable Session 1
List of experts available at the registration desk
8:00 a.m.-10:00 a.m.  **Session 1: Can We Diagnose Pancreatic Cancer Early?**  
*Session Chairperson: Michael G. Goggins, Johns Hopkins Medical Institutes, Baltimore, MD*

8:00 a.m.  **Characterization of pancreatic circulating tumor cells for novel biomarkers and therapeutic targets**  
David T. Ting, Massachusetts General Hospital Cancer Center, Boston, MA

8:25 a.m.  **A mouse to human search for pancreatic cancer markers**  
Samir M. Hanash, Fred Hutchinson Cancer Center, Seattle, WA

8:50 a.m.  **Molecular imaging and biomarker discovery in pancreatic cancer**  
Kimberly A. Kelly, University of Virginia, Charlottesville, VA

9:15 a.m.  **An engineered chimeric, Fc-mutated Anti-CA19-9 scFv-Fc for targeting pancreas cancer in an orthotopic model***  
James S. Tomlinson, VHA Greater Los Angeles Medical Center, Los Angeles, CA

9:30 a.m.  Panel Discussion

10:00 a.m.-10:30 a.m.  Break

10:30 a.m.-12:30 p.m.  **Session 2: Can Pancreatic Cancer Be Avoided?**  
*Session Chairperson: Gloria M. Petersen, Mayo Clinic College of Medicine, Rochester, MN*

10:30 a.m.  **Obesity, autophagy and inflammation: Common features in the pathogenesis and etiology of liver and pancreatic cancers**  
Michael Karin, University of California, San Diego, CA

10:55 a.m.  **Pancreatic cancer: Identifying those at high risk**  
Alison P. Klein, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD

11:20 a.m.  **Familial pancreatic cancer surveillance: Outcomes and natural history of 100 patients over a decade**  
Teresa A. Brentnall, University of Washington, Seattle, WA

11:45 a.m.  **Role of vitamin D receptor (VDR) gene polymorphisms for overall survival in pancreatic cancer: Genome-wide association and functional mechanistic studies***  
Federico Innocenti, University of North Carolina at Chapel Hill, Chapel Hill, NC

12:00 p.m.  Panel Discussion

12:30 p.m.-2:30 p.m.  **Poster Session A and Lunch**  
*Lakeside Ballroom*

*Short talks from proffered papers*
2:30 p.m.-4:30 p.m.  Session 3: How Does Pancreatic Cancer Develop?  
*Session Chairperson: Steven D. Leach, Johns Hopkins University School of Medicine, Baltimore, MD*

2:30 p.m.  Genomic analysis reveals roles for chromatin modification and axon guidance in pancreatic cancer  
Andrew V. Biankin, Garvan Institute of Medical Research, Sydney, Australia

2:55 p.m.  Using patient-derived xenografts for personalized medicine in pancreas cancer  
Manuel Hidalgo, Spanish National Cancer Center, Madrid, Spain

3:20 p.m.  Loss of the chromatin regulator Brg1 affects neoplasia and pancreatic cancer formation  
Matthias Hebrok, University of California, San Francisco, CA

3:45 p.m.  Association between ambient ultraviolet radiation at birth, skin type, skin cancer history, and pancreatic cancer*  
Rachel E. Neale, Queensland Institute of Medical Research, Brisbane, Australia

4:00 p.m.  Panel Discussion

4:30 p.m.-7:30 p.m.  Dinner Break (Dinner on your own)

7:30 p.m.-9:30 p.m.  Session 4: Why Does Pancreatic Cancer Metastasize and Cause Cachexia and Pain?  
*Session Chairperson: Michael A. Hollingsworth, University of Nebraska Medical Center Eppley Cancer Center, Omaha, NE*

7:30 p.m.  EMT and dissemination precede pancreatic tumor formation  
Ben Z. Stanger, Abramson Cancer Center of the University of Pennsylvania, Philadelphia, PA

7:55 p.m.  The role of pancreatic cancer stem cells in metastasis  
Zeshaan A. Rasheed, Johns Hopkins University School of Medicine, Baltimore, MD

8:20 p.m.  Cachexia, immune suppression, and the FAP+ stromal cell  
Douglas Fearon, Cancer Research UK Cambridge Research Institute, Cambridge, United Kingdom

8:45 p.m.  Neuroplastic changes and pain-related behavior in a transgenic mouse model of pancreatic ductal adenocarcinoma (PDAC)*  
Rachelle E. Stopczynski, University of Pittsburgh, Pittsburgh, PA

9:00 p.m.  Panel Discussion

*Short talks from proffered papers*
Wednesday, June 20

7:00 a.m.-8:00 a.m.   Continental Breakfast and
Meet-the-Expert Roundtable Session 2
List of experts available at the registration desk

8:00 a.m.-10:00 a.m.  Session 5: How Does the Tumor Microenvironment
Influence Pancreatic Cancer?
Session Chairperson: Sunil R. Hingorani, Fred Hutchinson
Cancer Research Center, Seattle, WA

8:00 a.m.  Dynamic and reciprocal force regulation of tumor progression
Valerie M. Weaver, University of California San Francisco Medical Center,
San Francisco, CA

8:25 a.m.  Inflammation and cancer: Reprogramming the immune microenvironment as
an anticancer therapeutic strategy
Lisa M. Coussens, Knight Cancer Institute, Oregon Health and Sciences
University, Portland, OR

8:50 a.m.  Immune surveillance and CD40 therapy of pancreatic cancer in mice and
humans
Robert H. Vonderheide, Abramson Cancer Center of the University of
Pennsylvania, Philadelphia, PA

9:15 a.m.  Macropinocytosis as a mechanism of amino acid supply*
Cosimo Commisso, New York University School of Medicine, New York, NY

9:30 a.m.  Panel Discussion

10:00 a.m.-10:30 a.m.  Break

*Short talks from proffered papers
10:30 a.m.-12:30 p.m.  **Session 6: Can KRAS Be Defeated?**  
*Session Chairperson: Channing J. Der, University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC*

10:30 a.m. **Targeting K-Ras for the treatment of pancreatic cancer**  
Stephen W. Fesik, Vanderbilt University School of Medicine, Nashville, TN

10:55 a.m. **Functional genomics and KRAS-driven cancers**  
William C. Hahn, Dana-Farber Cancer Institute, Boston, MA

11:20 a.m. **Targeting unique dependencies of RAS mutant tumors**  
Julian Downward, Cancer Research UK London Research Institute, London, United Kingdom

11:45 a.m. **Oncogenic Ras requires stimulation for activity sufficient to initiate a feed-forward inflammatory mechanism capable of inducing pancreatic diseases, including pancreatitis and cancer**  
Craig D. Logsdon, The University of Texas MD Anderson Cancer Center, Houston, TX

12:00 p.m. **Panel Discussion**

12:30 p.m.-2:30 p.m. **Poster Session B and Lunch**  
*Lakeside Ballroom*

2:30 p.m.-4:30 p.m. **Session 7: What Are the Promising Preclinical and Clinical Advances in Pancreatic Cancer?**  
*Session Chairperson: Margaret A. Tempero, University of California, San Francisco, CA*

2:30 p.m. **Targeting cancer stem cells in pancreatic cancer**  
Diane M. Simeone, University of Michigan Hospital and Health Systems, Ann Arbor, MI

2:55 p.m. **Altering drug delivery in pancreatic cancer: Development and clinical translation of smootherned inhibitors**  
Kenneth P. Olive, Columbia University Irving Comprehensive Cancer Center, New York, NY

3:20 p.m. **How much gemcitabine reaches the target... and does it matter?**  
Duncan I. Jodrell, Cambridge University, Cambridge, United Kingdom

3:45 p.m. **Clonal profiling of prospectively collected primary pancreatic ductal adenocarcinomas**  
Michael T. Barrett, Translational Genomics Research Institute, Scottsdale, AZ

4:00 p.m. **Panel Discussion**

*Short talks from proffered papers*
4:30 p.m.-5:00 p.m. Break

5:00 p.m.-7:00 p.m. Session 8: Are There New Ways to Prevent or Treat Pancreatic Cancer?
Session Chairperson: Anil K. Rustgi, Abramson Cancer Center of the University of Pennsylvania, Philadelphia, PA

5:00 p.m. Autophagy, metabolism, and pancreatic cancer
Alec C. Kimmelman, Dana-Farber Cancer Institute, Boston, MA

5:25 p.m. Regulation of metabolism to support tumor growth
Matthew G. Vander Heiden, David H. Koch Institute for Integrative Cancer Research at MIT, Cambridge, MA

5:50 p.m. Microenvironment and pancreatic cancer
Roland M. Schmid, Technical University of Munich, Klinikum rechts der Isar, Munich, Germany

6:15 p.m. Targeted therapy for pancreatic cancer*
Sanjay Awasthi, Beckman Research Institute, City of Hope, Duarte, CA

6:30 p.m. Panel Discussion

7:00 p.m.-8:30 p.m. Buffet Dinner
Lakeside Ballroom

8:30 p.m.-10:00 p.m. Keynote Presentations and Discussion: Progress Ahead for Pancreatic Cancer

8:30 p.m. Targeting KRAS directly
Frank McCormick, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA

9:00 p.m. Kras-directed anabolic processes in PDAC tumor maintenance
Ronald A. DePinho, The University of Texas MD Anderson Cancer Center, Houston, TX

9:30 p.m. Discussion

Closing Remarks

Thursday, June 21

Departure